Pasithea Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference

Pasithea Therapeutics will present at the H.C. Wainwright 27th Annual Global Investment Conference, with CEO Dr. Tiago Reis Marques delivering a live company presentation and management available for one-on-one meetings. The company is focused on developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of RASopathies, MAPK pathway-driven tumors, and other diseases. Pasithea is currently testing PAS-004 in Phase 1 clinical trials.

Pasithea Therapeutics (NASDAQ: KTTA), a clinical-stage biotechnology company, will participate in the upcoming H.C. Wainwright 27th Annual Global Investment Conference. The company's CEO, Dr. Tiago Reis Marques, will deliver a presentation on September 10, 2025, at 2:30 PM ET at the Lotte New York Palace Hotel. Pasithea is currently developing PAS-004, a next-generation macrocyclic MEK inhibitor. Management will be available for one-on-one meetings throughout the conference, which runs from September 8-10, 2025 [1].

Pasithea Therapeutics is focused on the research and development of its lead drug candidate, PAS-004, which is intended for the treatment of RASopathies, MAPK pathway-driven tumors, and other diseases. The company is currently testing PAS-004 in a Phase 1 clinical trial in advanced cancer patients (NCT06299839) and a Phase 1/1b clinical trial in adult patients with neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas (NCT06961565) [2].

The H.C. Wainwright 27th Annual Global Investment Conference is a significant event for investors and financial professionals to network and learn about the latest developments in the biotechnology sector. Pasithea's participation provides an opportunity for investors to gain insights into the company's ongoing clinical trials and future plans.

The company's CEO, Dr. Tiago Reis Marques, will present a live company overview, followed by one-on-one meetings with management. This engagement will allow investors to ask questions and receive detailed information about PAS-004 and Pasithea's strategic direction.

Pasithea Therapeutics' participation in this prestigious event underscores its commitment to transparency and investor relations. The company's focus on developing innovative treatments for complex diseases positions it as a promising player in the biotechnology sector.

References:
[1] https://www.stocktitan.net/news/KTTA/pasithea-therapeutics-to-present-at-the-h-c-wainwright-27th-annual-shsx7jet6h2l.html
[2] https://www.marketscreener.com/news/pasithea-therapeutics-to-present-at-the-h-c-wainwright-27th-annual-global-investment-conference-ce7c50dfde8df52d